Glenmark Life Sciences Limited IPO (Glenmark Life Sciences IPO) Detail

Add to Calendar 2021-07-27 12:00 AM 2021-07-29 12:00 AM Asia/Kolkata Glenmark Life Sciences Limited IPO (Glenmark Life Sciences IPO) Detail Glenmark Life Sciences Limited India

Glenmark Life Sciences (GLS) is the latest among the slew of IPOs to hit the market in the next few days. The IPO has an issue size of Rs. 1,514 crores comprising of a fresh issue aggregating to Rs. 1,060 crore and an offer for sale of Rs. 454 crores. The price band has been set between Rs. 695 to Rs. 720 per share for a lot size of 20 shares. Post the issue, the implied market capitalization of the company is expected to stand between Rs. 8,552 and 8,822 crores based on the lower and upper price bands, respectively. Currently, the promoters hold 100.00 percent of the shares. Post listing the shares held by promoters will be diluted to 82.84 percent.

Company Overview:

GLS is the wholly owned subsidiary company of Glenmark Pharmaceuticals, a global pharmaceutical company. It is a leading developer and manufacturer of select high value, non-commoditized APIs in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. The company operates two business lines, namely – Generic API and Contract Development and Manufacturing Operations (CDMO). The company has a portfolio of 120 molecules globally. 

The API portfolio comprises of specialized, niche and technically complex molecules. The CDMO business currently comprises of obtaining permission to market products in regulated markets and contract manufacturing of APIs.

Financial Snapshot:

(in Rs. Crore)

FY19

FY20

FY21

3 - year CAGR

Revenue

886

1,537

1,885

45.8 Percent

EBITDA

248

472

591

54.5 Percent

EBITDA Margin ( Percent)

27.9 Percent

30.7 Percent

31.4 Percent

-

PAT

196

313

352

34.1 Percent

PAT Margin ( Percent)

22.1 Percent

20.4 Percent

18.6 Percent

-

EPS

24.64

29.04

32.61

15.0 Percent

Net Worth

88

402

753

192.5 Percent

Debt (payable to parent)

1,162

1,059

933

-

ROE

99.25 Percent

77.94 Percent

46.71 Percent

-

ROCE

32.17 Percent

30.77 Percent

32.69 Percent

-


Revenue, EBITDA and net profit have seen stellar growth on a CAGR basis in the last three years. EBITDA margin has also improved steadily but the net profit margin witnessed a downtrend on account of higher interest costs on the liability owed to the parent, Glenmark.

GLS owed Rs. 933 crores to its parent as on March 31, 2021. This amount had reduced to Rs. 800 crores as on July 9, 2021. The IPO proceeds would be used to pay off this debt completely which will reduce interest costs going forward. The company has witnessed a robust growth in cash flow and stands with a healthy cash balance of Rs. 116 crores. 

ROCE has risen steadily to 32.69 percent and is one of the highest among peers. ROE, on the other hand, saw a sharp downfall which was mainly on account of a gradually increasing equity base, as is the case with a newly spun-off / formed company. Nevertheless, ROE at 46.71 percent was the highest in the industry.

Manufacturing Prowess and R&D Capabilities:

With four manufacturing facilities located at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra, GLS boasts of a combined capacity of 726.6 KL with an average capacity utilization of 82 percent. They intend to increase their API manufacturing capabilities by enhancing existing production capacities at Ankleshwar during FY22 and Dahej during FY22-23 by 200 KL. Additionally, the company will set up a new greenfield project which should be functional by Q4 FY23 and will reach a capacity of 800 KL in the next 3 to 4 years. The capex for this new facility would be funded from internal accruals and debt (if required).

R&D operations are fulfilled through three dedicated R&D units with a headcount of 213 employees. Expenditure on R&D activities at 2.15 percent, 2.60 percent and 2.67 percent of total revenue from operations in FY21, FY20 and FY19, respectively showed a downtrend. As of May 31, 2021, they own / co-own 39 granted patents and had 41 patents pending approval in different countries. They intend to introduce 8-10 new molecules every year. 

Strengths:

  • Leadership in select high value, non-commoditized APIs in chronic therapeutic areas.

  • Strong relationships with leading global generic companies. 16 of the 20 largest generic customers globally were their customers. Approximately 69 percent of the customers were period-on-period repeat customers since FY19.

  • Cost leadership across products through careful monitoring and continuous effort.

  • Quality-focused compliant manufacturing and R&D infrastructure. GLS has not received any warning letters or import alerts from any regulatory authorities.

  • As mentioned earlier, the company demonstrates a strong financial profile and healthy profitability.


However, the company does have a few risks:

  • Customer concentration – Their top 5 customers contribute 54.35 percent of the revenue which gives them great bargaining power. Loss of any major customer could adversely affect the topline.

  • A significant portion of revenue is derived from a few key products. Increased competition, pricing pressure, fluctuation in demand or supply of products, breakthroughs in development of alternative drugs, could trigger a decline in the earning capability.

  • As much as 40 percent of the company’s raw materials are sourced from China. Geopolitical tensions could hamper production. On the upside, dependance on China for raw materials has gradually decreased.

  • Conflicts may arise in negotiation and dealing with Glenmark Pharmaceuticals, with respect to the contractual arrangements. The parent company is their largest customer and with no non-compete agreement in place, GLS’ business could be adversely impacted.

  • Increasing number of receivables have been unpaid for more than 180 days. Any further delay in receipt could impact operations as GLS has a large requirement for working capital.


Conclusion:

Company

P/E

ROE

ROCE

Glenmark Life Sciences

22.08x

46.7 Percent

32.7 Percent

Divi’s Laboratories

63.65x

23.9 Percent

32.0 Percent

Laurus Labs

36.59x

45.2 Percent

39.6 Percent

Shilpa Medicare

33.37x

10.5 Percent

8.0 Percent

Aarti Drugs

24.28x

35.8 Percent

34.7 Percent

Solara Active Pharma

25.83x

17.2 Percent

16.0 Percent


GLS has the lowest P/E and a fair P/S in comparison to its peers, but provides superior returns to shareholders. Moreover, the company is a market leader in select APIs backed by strong parentage and demonstrates good financial health, which makes it attractive at the price offered. Thus, we recommend investors who are looking for listing gains to subscribe to the IPO.


You can also watch our IPO Review video here - Glenmark Life Sciences Limited IPO Review

Issue Detail

  • Issue Open: Jul 27, 2021
  • Issue Close: Jul 29, 2021
  • Issue Type: Book Built Issue IPO
  • Face Value: Rs. 2 per equity share
  • Price Band: Rs. 695 to Rs. 720 per equity share
  • Bid Lot:20 Shares
  • Minimum Order Quantity:20 Shares
  • Listing At: BSE, NSE
  • Issue Size: • Rs. 1,513.60 Cr

Current Bidding Status

Number of Times Subscribed (BSE + NSE)
As on Date & Time QIB NII RII Employee Others Total

Listing Day Trading Information

- BSE NSE
Issue Price - -
Open - -
Low - -
High - -
Last Trade - -
Volume - -

Glenmark Life Sciences Limited Red Herring Prospectus

Glenmark Life Sciences Limited User Rating

Votes
0

Glenmark Life Sciences Limited Life IPO Reviews

Glenmark Life Sciences Limited IPO News & Updates

Frequently Asked Questions

Yes, you can always trade an IPO through a discount broker. Buying & selling an IPO becomes very easy once the trading and the demat account are set up appropriately.
Following are the benefits in buying and selling an IPOs through a discount broker. Reduced Brokerage Fee: Discount brokers charge a flat brokerage which is missing in case of full service brokers. Full service brokers usually charge %age brokerage and this incurs a lot of cost to an investors. So if any full service broker charge a brokerage of let say 0.03% then on a purchase of shares of worth of Rs 200,000 you end up paying Rs 600+ Taxes. In our case we charge a flat brokerage of Rs 20 + Taxes. Discount brokers therefore saves a lot of money of investors. Better Trading Platform: Usually discounts brokers don’t provide a good trading platform and experience but there are few discounts brokers like Samco, who are now focussing on delivering a world class trading platform and top notch user experience. Therefore narrowing down the gap between discount brokers and full service brokers.
Technically Speaking, SEBI has made mandatory to buy an IPO through ASBA channel but there is no regulation on how any investor can sell an IPO allotted shares. Therefore, smart investors can always sell IPO allotted shares through a discount broker

Comments

Start IPO Trading through SAMCO

Don't have a Trading Account !!!
Open an account with Samco and Do IPO Trading for Just Rs 20. For more details, share your contact details with us